Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06744296 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

Study acronym: MRD-DUCHESS
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updatedv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 6, 2025 to Feb 3, 2025
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.
Trial Details
NCT Number NCT06744296
Lead Sponsor Massachusetts Eye and Ear Infirmary
Collaborators: Haystack Oncology, Inc.
Conditions
(from sponsor)		 Squamous Cell Carcinoma of Head and Neck
Related terms Squamous Cell Carcinoma of Head and Neck
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov